Skip to content
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
    • Investor Contact
  • News & Media
    • News Releases
  • Healthcare Professionals
    • Therapeutic Areas
    • Scientific Publications
    • Medical Information Request
  • Careers
    • Life at Acadia
    • Why Work At Acadia
    • Acadia Job Listings
Important Note
This page is intended as an educational resource for U.S. healthcare professionals. The list of Acadia-sponsored publications below may contain information about doses, uses, formulations and populations different from product labelling or contain information about investigational compounds or uses not approved by the FDA.

I certify that I am a licensed health care provider in the U.S.
YES
NO
Important Note
You are about to leave acadia.com. You will be redirected to a third party website not affiliated with Acadia Pharmaceuticals Inc.
Do you want to continue?

YES
NO
Acadia logo

Acadia Pharmaceuticals

  • About
    About
    Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most.
    Learn More
    • Acadia Leadership Team
    • History
    • Corporate Social Responsibility
    • Diversity, Equity & Inclusion (DE&I)
  • Our Medicines
    Our Medicines
    Learn more about our FDA-approved treatments for Parkinson’s Disease Psychosis and Rett syndrome.
    • NUPLAZID® (pimavanserin)
    • DAYBUE™ (trofinetide)
  • Pipeline
  • Therapeutic Areas
    Therapeutic Areas
    At Acadia, we see promise in therapeutic areas where the unmet need remains high.
    Learn More
    • Parkinson’s Disease Psychosis
    • Alzheimer’s Disease Psychosis
    • Negative Symptoms of Schizophrenia (NSS)
    • Rett Syndrome
  • Patients
  • Perspectives
  • Resources
    Resources
    At Acadia, we provide resources to further advance the innovative work of industry leaders, strategic partners and rigorous clinicians.
    • Strategic Partnerships
    • Clinical Trials
    • Investigator-Initiated Studies
    • Corporate Sponsorships
    • Independent Medical Education Grants
  • About Acadia
    Back
    About Acadia
    • Acadia Leadership Team
    • History
    • Corporate Social Responsibility
    • Diversity, Equity & Inclusion (DE&I)
  • Our Medicine
    Back
    Our Medicine
    • Nuplazid® (pimavanserin)
    • Daybue™ (trofinetide)
  • Product Pipeline
  • Therapeutic Areas
    Back
    Therapeutic Areas
    • Parkinson’s Disease Psychosis
    • Alzheimer’s Disease Psychosis
    • Negative Symptoms of Schizophrenia (NSS)
    • Rett Syndrome
  • Patients
  • Acadia Perspectives
  • Resources
    Back
    Resources
    • Strategic Partnerships
    • Clinical Trials
    • Investigator-Initiated Studies
    • Corporate Sponsorships
    • Independent Medical Education Grants
  • Investors
    Back
    Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
    • Investor Contact
  • News & Media
    Back
    News & Media
    • News Releases
  • Healthcare Professionals
    Back
    Healthcare Professionals
    • Therapeutic Areas
    • Publications
    • Request Medical Information
  • Acadia Careers
    Back
    Acadia Careers
    • Life at Acadia
    • Why Work At Acadia
    • Acadia Job Listings

Publications Therapeutic Area: Dementia-related Psychosis

Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States

Relapse in dementia-related psychosis and clinical decisions

Unmet needs in the diagnosis and treatment of dementia-related psychosis and Parkinson’s disease psychosis

Symptoms and treatment needs of people with dementia-related psychosis: a mixed-methods study of the patient experience

Healthcare resource utilization and costs for newly diagnosed dementia-related psychosis

Economic evaluation of healthcare resource utilization and costs for newly diagnosed dementia-related psychosis

Barriers to treatment of hallucinations and delusions in people with dementia residing in long-term care

Comparative outcomes of commonly used off-label atypical antipsychotics in the treatment for dementia-related psychosis: a network meta-analysis

Adverse outcomes associated with off-label agents used to treat dementia patients with psychosis: a case-control Medicare database study

Acadia logo

© 2023 Acadia Pharmaceuticals Inc. All rights reserved.

  • Privacy Policy
  • Privacy Shield
  • Compliance Policy
  • Accessibility
  • Community Guidelines
  • Contact Us
  • LinkedIn
  • Twitter
  • Sitemap
  • Terms of Use
  • Cookies Policy